Mosaic Biosciences’ Post

💡 𝑯𝒐𝒘 𝒄𝒂𝒏 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒐𝒓𝒔 𝒂𝒕𝒕𝒓𝒂𝒄𝒕 𝒇𝒖𝒏𝒅𝒊𝒏𝒈 𝒘𝒉𝒆𝒏 𝒘𝒐𝒓𝒌𝒊𝒏𝒈 𝒊𝒏 𝒂 𝒏𝒐𝒗𝒆𝒍 𝒇𝒊𝒆𝒍𝒅? Especially now when the investment landscape is so tough!     While working on our RNA therapeutics whitepaper, Guillermo Tramontin and I posed this question to Alessandro Toniolo, a seasoned CEO at Resalis Therapeutics and renowned for his leadership of biotech and pharmaceutical firms.      His answer: “A strong team with a clear strategy, consistent results, and a clear plan to address the inevitable issues that emerge when proceeding in an unexplored field.”  You can find plenty more straight-to-the-point, actionable insights from our conversation with Alessandro here https://lnkd.in/e8WKZVTg.      #rnatherapeutics #biotech #pharma #venturecapital #clinicaldevelopment 

FreeOx Biotech Formally Launches Seed Round to Fund Phase III Pivotal Trial — MediaContacts.co — Planned Phase III for Ox-01 to #Begin in #AIS in #Early 2025 • Pivotal #Trial to Evaluate #Novel Adjunct #Drug for Mechanical Thrombectomy BARCELONA, #Spain #Dec #5 #2023 FreeOx Biotech #SL a late-stage clinical biopharmaceutical #company pioneering the #development of a novel drug #class for Acute Ischemic #Stroke

🔬💊 Both academia and the pharma industry are working toward a common goal of improving the health of patients through the translation of molecular and cellular insights into novel therapeutics. George Vratsanos, MD & Dawn Waterworth, PhD believe that collaboration between industry and academia is key to continuing innovation and addressing unmet needs for patients. Find out more in the full article from Life Science Leader below ⤵ #LifeSciences #Pharma #BioPharma

🔬💊 Both academia and the pharma industry are working toward a common goal of improving the health of patients through the translation of molecular and cellular insights into novel therapeutics. George Vratsanos, MD & Dawn Waterworth, PhD believe that collaboration between industry and academia is key to continuing innovation and addressing unmet needs for patients. Find out more in the full article from Life Science Leader below ⤵ #LifeSciences #Pharma #BioPharma

Introducing the first 5 confirmed speakers for Biologics Manufacturing 5.0 2024 London, UK.     Jan F Talts – Amniotics AB Hani Gabra – Papyrus Therapeutics Inc. Kwangjun Yoon – CHA Bio Group｜차바이오그룹 Jean-François Dierick – GSK Victor Dillard– Resolution Therapeutics   Join in and learn about: AI for continuous manufacturing, real-time modeling in commercial production, and cloud-based collaboration. We also explore Cell Line Development, Raw Materials, ICH guidelines, streamlined processing, continuous manufacturing integration, and process intensification. This strategy enhances efficiency and productivity, involving process modeling, control, and advanced analytics, offering cost reduction and higher titers while maintaining quality.     Learn more about #BM5 2024 here: https://lnkd.in/eMHdYQM2     Will we see you there?    #BiologicsManufacturing #Bioprocessing #AIinBiopharma #Industry5.0 #AIinManufacturing #InnovationInBiopharma #IMAPAC 

The American Association of Pharmaceutical Scientists (AAPS) | @aapscomms National Biotechnology Conference (NBC) #NBC2024 takes place in 13-16 May in San Francisco. Topics include Targeted Therapeutics Delivery, Formulation/Pre-formulation of biologics, AI/ML in Discovery & Development, and of course Bioanalysis! The deadline for poster submission is now just under 5 weeks away. Submit a scientific programming proposal for the 2024 NBC. And, if you ever wondered why it isn't "easy" to get an abstract submitted to an AAPS conference, including the NBC, see the 4 bullets below:

🔬💊 Both academia and the pharma industry are working toward a common goal of improving the health of patients through the translation of molecular and cellular insights into novel therapeutics. George Vratsanos, MD & Dawn Waterworth, PhD believe that collaboration between industry and academia is key to continuing innovation and addressing unmet needs for patients. Find out more in the full article from Life Science Leader below ⤵ #LifeSciences #Pharma #BioPharma

📢Fujifilm's $12 Billion Expansion Revolutionizes Biomanufacturing in North Carolina 📢 Fujifilm has invested an additional $1.2 billion in its North Carolina CDMO to expand its biomanufacturing facility. 🏭 The investment will add 8 new 20,000-liter mammalian cell culture bioreactors by 2028. 💰 The facility will be one of the largest cell culture biopharmaceutical CDMO facilities in North America. 💼 The expansion allows Fujifilm to construct identical large-scale production facilities in the US and Europe. 🌍 The facility will incorporate sustainability initiatives and aims to achieve LEED Gold Certification. #BioprocessUpdates #FujifilmInvestment #NorthCarolinaCDMO #BiomanufacturingExpansion #MammalianCellCulture #Bioreactors2028 #CellCultureBiopharmaceutical #CDMOFacilities #LargeScaleProduction #USandEurope #SustainabilityInitiatives #LEEDGoldCertification #FujifilmExpansion #BiotechInvestment #PharmaceuticalIndustry #BusinessExpansion ▷ Read the full article here: 📎 https://lnkd.in/deDccJ3h

At Acuitas, we work with global partners to develop new therapies to address unmet clinical needs based on our best-in-class lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics.   Our business model is unique. It allows us to lead the field in LNP innovation and in how we work with partners in the development of new therapeutics. Check out this video to learn about our business model – and why we are the first-choice partner for pharmaceutical, biotechnology, NGOs, academics and other research organizations. #acuitastherapeutics #mRNA #lipidnanoparticles #humanhealth #vaccines

I like this configuration.